BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the ...
Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following ...
The vaccine space has been battered by strong headwinds in recent weeks, including high-level disruptions to FDA and CDC ...
The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for ...
BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
BioNTech's early-to-mid stage trial of an experimental malaria vaccine has been put on a clinical hold by the U.S. Food and ...
In a regulatory filing, BioNTech (BNTX) disclosed that the U.S. Food and Drug Administration has informed BioNTech SE that it has placed a ...
HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...
The trial was to evaluate the safety and efficacy of the RNA-based vaccine called BNT165e for prevention of malaria caused by ...
The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...